Prognostic role of novel inflammatory biomarkers in patients with chronic obstructive pulmonary disease with metabolic syndrome

<bold>Background:</bold> The value of biomarkers for the assessment of the course of chronic obstructive pulmonary disease (COPD) is crucial. Metabolic syndrome (MetS) is characterised by the clustering of several risk factors and coexisting MetS in patients with COPD deteriorates quality of life and the prognosis. The purpose was to evaluate the predictive ability of inflammatory biomarkers such as lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in patients with COPD and MetS. <bold>Material and Methods:</bold> A total of 125 inpatients with COPD and MetS and 62 controls with COPD were enrolled between 2021 to 2023. Baseline anthropometric, laboratory, and instrumental examination data were collected. AUC ROC was used to measure their predictive value for COPD and MetS. <bold>Results:</bold> The NLR and LMR were higher in patients with COPD and MetS than in COPD without MetS patients (P<0.05), whereas the PLR was significantly lower (P<0.05). The OR values of the NLR, PLR, and LMR were 1.17 (1.12-1.24), 0.87(0.86-0.89) and 1.21(1.08-1.25), respectively (P<0.05). After adjusting for confounding factors, NLR was still the most significant risk factor for COPD and MetS compared with other inflammatory markers (P<0.05). The AUCs of the NLR, PLR, and LMR were as follows: 0.475 (0.465-0.485), 0.42 (0.41-0.43), and 0.48 (0.46-0.49), respectively (P<0.05). Besides, the diagnostic model combining the NLR with CRP, blood glucose, and abdominal obesity had the better AUC of 0.874 (0.864-0.884). <bold>Conclusion:</bold> NLR was superior as a biomarker in the prediction of COPD and MetS, and may improve diagnostic accuracy with other parameters.